Delphine Réa - Concepedia

Author

Delphine Réa

Also Known As

Agnès-Paule Guerci-Bresler, Andreas Burchert, Aude Charbonnier, Brümmendorf, Tim H., D Rea, D Réa, D. Rea, D. Réa, DELPHINE REA, Delphine Rea

416

Publications

19.6K

Citations

H-Index

Concepts

All Affiliations

Hôpital Saint-Louis Inserm Institut Bergonié Jena University Hospital Assistance Publique – Hôpitaux de Paris

About

Delphine Réa is an author at Hôpital Saint-Louis specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	49	5.7K
2	Health Sciences	15	19	2.7K
3	Engineering	1	1	26
4	Public Health	1	1	31
5	Allergy	1	1	205

Delphine Réa

161

Publications

15.8K

Citations

H-Index

Page 1

	Year	Citations
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial François‐Xavier Mahon, Delphine Réa, Joëlle Guilhot, The Lancet Oncology Hematological MalignancyOncologyChronic Myeloid LeukaemiaHematologyMyeloid Neoplasia	2010	1.5K
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias Jörge E. Cortes, D. W. Kim, Javier Pinilla‐Ibarz, New England Journal of Medicine	2013	1.1K
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial Johan Richter, Joëlle Guilhot, Franz Gruber, The Lancet Oncology Hematological MalignancyMedicineChronic Myeloid LeukaemiaMixed-phenotype Acute LeukemiaHematology	2018	587
Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial Jörge E. Cortes, Dong‐Wook Kim, Javier Pinilla‐Ibarz, Blood	2018	572
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years Philippe Rousselot, Françoise Huguet, Delphine Réa, Blood	2006	528
Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia Neil P. Shah, Hagop M. Kantarjian, Dong‐Wook Kim, Journal of Clinical Oncology	2008	487
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia Gabriel Étienne, Joëlle Guilhot, Delphine Réa, Journal of Clinical Oncology Hematological MalignancyStop ImatinibChronic Myeloid LeukemiaPurpose ImatinibMedicine	2016	484
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure Timothy P. Hughes, Michael J. Mauro, Jörge E. Cortes, New England Journal of Medicine	2019	449
Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease Philippe Rousselot, Aude Charbonnier, Pascale Cony‐Makhoul, Journal of Clinical Oncology	2013	405
Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia Claude Preudhomme, Joëlle Guilhot, Franck E. Nicolini, New England Journal of Medicine	2010	382

Page 1